Compare AbCellera Biologics Inc (ABCL) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs SiTime Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while SiTime Corporation trades at $609.25 (market cap $17.74B). The key difference: SiTime Corporation is far larger — about 7.5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | SITM | |
|---|---|---|
Market Cap | $2.35B | $17.74B |
Sector | Health | Technology |
52-Week High | $8.12 | $901.60 |
52-Week Low | $2.78 | $190.16 |
Enterprise Value | $1.99B | $16.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SITM trades at $615.46, up 2.29% today, showing strong momentum with three consecutive quarterly earnings beats. The stock faces technical headwinds with a bearish moving average signal, while fundamentals reveal robust revenue growth but negative profitability metrics. Recent news highlights the completed acquisition of Renesas' timing business and strong AI-driven demand, with management raising full-year growth guidance to at least 80%.
The outlook remains promising due to accelerating AI infrastructure demand and strategic acquisitions, though investors face risks from negative profit margins and high valuation multiples. Analyst consensus is unanimously bullish with a $743.75 price target representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
